Related Experiment Video

Updated: Jul 15, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors

Margaret von Mehren1

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. margaret.vonmehren@fccc.edu

Clinical Colorectal Cancer
|April 11, 2007
PubMed

Insights

Gastrointestinal stromal tumors (GISTs) are common cancers treated with imatinib. New therapies are being developed for imatinib-resistant GISTs, offering hope for improved patient outcomes.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GISTs) are the most prevalent mesenchymal malignancies of the gastrointestinal tract.
  • KIT expression is a defining characteristic of GISTs.
  • Imatinib, a tyrosine kinase inhibitor (TKI), effectively treats metastatic GISTs by targeting KIT and platelet-derived growth factor receptor.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for gastrointestinal stromal tumors (GISTs).
  • To address the clinical challenge posed by GISTs refractory to imatinib therapy.
  • To highlight novel agents and combinations under clinical investigation.

Main Methods:

  • Review of clinical trials and therapeutic agents for GIST management.
  • Focus on tyrosine kinase inhibitors (TKIs) and other targeted therapies.
  • Evaluation of agents in various stages of clinical development, including imatinib-refractory cases.

Main Results:

  • Sunitinib is an established multitargeted TKI for imatinib-refractory GISTs.
  • Ongoing trials are assessing novel KIT TKIs like AMG 706 and AMN 107 (nilotinib).
  • Combinations of imatinib with RAD001, PKC412, and bevacizumab are under investigation.
  • The heat-shock protein-90 inhibitor IPI-540 is in Phase I trials for imatinib-refractory GISTs.

Conclusions:

  • The therapeutic landscape for GIST is expanding with new agents.
  • Improved understanding of GIST biology will guide personalized treatment strategies.
  • Future management will likely involve a broader array of targeted therapies tailored to specific patient populations.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...